secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2026-07-17T13:20:50+00:00
Accession:  0001213900-26-078937
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Chairman and CFO resign; Uri Tadelis appointed as new CFO
---------------------------------------------------------

- Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026.
- Guy Ofir resigned as CFO, General Counsel, and Director effective July 16, 2026.
- Both resignations were not due to any disagreement with the company.
- Uri Tadelis appointed as CFO effective July 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/ea0298326-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-078937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer